A Phase 3 interventional study of Mavacamten and Placebo in Cardiomyopathy, Hypertrophic, sponsored by Bristol-Myers Squibb. Terminated at 224 sites in 23 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-18.
Sponsored by Bristol-Myers Squibb · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 22 studies testing MYK-461 in Cardiomyopathy, Hypertrophic — 4 open to participants now, 8 under way, 2 of them phase 3. MYK-461 · Cardiomyopathy, Hypertrophic.
Among the 22 studies testing MYK-461 in Cardiomyopathy, Hypertrophic, this one has the largest enrollment, is one of 4 that started in 2022, is one of 7 in phase 3, and was the 13th registered.
364 studies on the registry are indexed under Cardiomyopathy, Hypertrophic; 117 are open to participants now.
Browse Cardiomyopathy, Hypertrophic studies →4 of the 22 studies testing MYK-461 in Cardiomyopathy, Hypertrophic are open now, in 2 countries. Recruiting first, the newest first:
University of Manchester · Sites in United Kingdom
Ages 18+
Second Affiliated Hospital, Zhejiang University, School of Medicine · Sites in China
Ages 18–75
Bristol-Myers Squibb
Ages 18–85
Second Affiliated Hospital of Nanchang University
Ages 18+
By country, each count listing its studies:
MYK-461: first FDA approval 2022 (CAMZYOS), first EMA approval 2023. What it is approved for, and how studies give it, is on its page →
Of the 81 Cardiomyopathy, Hypertrophic studies recruiting now, 55 (68%) set no upper age limit and 8 (10%) stop at 75 or younger; 21 take children under 18; 13 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
22 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 4 · Phase 3 8 · Phase 4 4
First in 2014; this study’s year is marked. 4 started in 2022.
This study's enrollment of 580 is above the median of 60 across 181 interventional studies indexed under Cardiomyopathy, Hypertrophic.
Median enrollment 77 across the 22 interventional studies. Of the 14 that completed or were terminated, 9 (64%) have results posted.
This tab as a report to print or save as PDF → With an account.
18 of 22 have an industry lead sponsor. The 7 most frequent:
Bristol-Myers Squibb is the lead sponsor of 1,562 studies on the registry; 119 are open to participants now.
Of its 436 completed or terminated interventional studies of FDA-regulated products, 228 (52%) have results posted.
32 studies in Cardiomyopathy, Hypertrophic by Bristol-Myers Squibb: 10 open now, 15 under way, 2 of them phase 3. Of 17 finished, 8 (47%) have results posted.
Among the 32 studies in Cardiomyopathy, Hypertrophic by Bristol-Myers Squibb, this one has the largest enrollment of the 17 interventional ones that give a count, is one of 4 that started in 2022, is one of 6 in phase 3, and was the 12th registered.
Bristol-Myers Squibb’s Cardiomyopathy, Hypertrophic studies by the year they started, since 2014.
None of the studies under way reaches primary completion within a year.
Among the 22 studies testing MYK-461 in Cardiomyopathy, Hypertrophic, from their registry updates:
Among Bristol-Myers Squibb’s 32 in Cardiomyopathy, Hypertrophic:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the safety, tolerability, and efficacy of mavacamten compared with placebo in participants with symptomatic non-obstructive hypertrophic cardiomyopathy (nHCM).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Mavacamten
Other: Placebo
Specified dose on specified days
Also known as: BMS-986427, MYK-461
Specified dose on specified days
Change From Baseline in KCCQ-23 CSS at Week 48
The KCCQ-23 is a 23-item, self-administered questionnaire that measures the impact of a participant's cardiovascular disease or its treatment on 6 distinct domains using a 2-week recall period: symptoms/signs, physical limitation, quality of life (QoL), social limitations, self-efficacy, and symptom stability. The KCCQ 23 Clinical Summary Score (CSS) is derived from the Total Symptom Score (TSS) and the Physical Limitations (PL) score of the KCCQ 23. The CSS, TSS, and the PL score range from 0 to 100 with higher scores representing less severe symptoms and/or physical limitations. The CSS is a mean of the TSS and the PL score. Baseline is defined as the last non-missing assessment prior to the first dose of the study treatment if both the time of the measurement and the time of first dose are available otherwise it is the last non-missing assessment on or prior to the first dose of the study treatment.
Time frame: From First dose to week 48
Change From Baseline in pVO2 at Week 48
Clinically meaningful mean change from baseline(1.4ml/kg/min) of pVO2 at Week 48.
Time frame: From First dose to week 48
Change From Baseline in VE/VCO2 Slope at Week 48
VE/VCO₂ slope was assessed using cardiopulmonary exercise testing (CPET). The slope was calculated as the linear regression of minute ventilation (VE) against carbon dioxide production (VCO₂). A decrease in VE/VCO₂ slope reflects improved ventilatory efficiency.
Time frame: From First dose to week 48
Mean Change From Baseline in NT-proBNP to Week 48
Blood samples were collected for assessing the concentration of NT-proBNP. Baseline is defined as last non-missing measurement prior to the first dose.
Time frame: From First dose to week 48
Percentage of Participants With at Least 1 Class of NYHA Improvement From Baseline at Week 48
Participants with \\\>= 1 NYHA function class improvement. The NYHA Functional Classification of heart failure assigns participants to 1 of 4 categories based on the participant's symptoms. Class 1: No limitation of physical activity. Ordinary physical activity does not cause undue fatigue, palpitation, dyspnea (shortness of breath). Class 2: Slight limitation of physical activity. Comfortable at rest. Ordinary physical activity results in fatigue, palpitation, dyspnea (shortness of breath). Class 3: Marked limitation of physical activity. Comfortable at rest. Less than ordinary activity causes fatigue, palpitation, or dyspnea. Class 4: Unable to carry on any physical activity without discomfort. Symptoms of heart failure at rest. If any physical activity is undertaken, discomfort increases.
Time frame: From First dose to week 48
Mean Change From Baseline in HCMSQ SoB Domain Score at Week 48
The HCMSQ is a self- administered, 9-item questionnaire that assesses the core symptoms of HCM (shortness of breath, tiredness/fatigue, heart palpitations, chest pain, dizziness, and syncope). At each visit, a 7-day period will be defined, ending on the last day with a non-missing HCMSQ score prior to the actual clinic visit (or first dose date if baseline). If the participant completes the HCMSQ for 4 or more days within this period, the weekly average HCMSQ score will be calculated. If fewer than 4 days are completed, other 7-day periods will be considered. For baseline, any 7-day period with at least 4 days of HCMSQ prior to the first dose or randomization date (if first dose date is missing) will be used. Each domain of the SoB scale is scored 1 to 6. The scores are added together to give a total score. Lower scores indicating low to no shortness of breath, higher scores indicating frequent episodes of shortness of breath. the lower the score the better.
Time frame: From First dose to week 48
| Milestone | Treatment 1 | Treatment 2 |
|---|---|---|
| Started | 289 | 291 |
| Completed | 258 | 274 |
| Not completed | 31 | 17 |
| Withdrew: Lost to follow-up | 0 | 1 |
| Withdrew: Non-compliance with study drug | 0 | 1 |
| Withdrew: Physician decision | 3 | 0 |
| Withdrew: Participant request to discontinue | 4 | 6 |
| Withdrew: Withdrawal by subject | 2 | 1 |
| Withdrew: Adverse event | 12 | 5 |
| Withdrew: Lvef permanent discontinuation criteria met | 7 | 0 |
| Withdrew: Other reasons | 3 | 3 |
| Milestone | Treatment 1 | Treatment 2 |
|---|---|---|
| Started | 289 | 291 |
| Completed | 0 | 0 |
| Not completed | 289 | 291 |
| Withdrew: Lost to follow-up | 0 | 1 |
| Withdrew: Non-compliance with study drug | 0 | 1 |
| Withdrew: Physician decision | 4 | 1 |
| Withdrew: Study closed out early due to sponsor | 251 | 259 |
| Withdrew: Participant request to discontinue treatment | 4 | 12 |
| Withdrew: Withdrawal by subject | 3 | 3 |
| Withdrew: Adverse event | 15 | 8 |
| Withdrew: Lvef permanent discontinuation criteria met | 7 | 1 |
| Withdrew: Other reasons | 5 | 5 |
VE/VCO₂ slope was assessed using cardiopulmonary exercise testing (CPET). The slope was calculated as the linear regression of minute ventilation (VE) against carbon dioxide production (VCO₂). A decrease in VE/VCO₂ slope reflects improved ventilatory efficiency.
| ratio | Treatment 1 | Treatment 2 |
|---|---|---|
| Change From Baseline in VE/VCO2 Slope at Week 48 | -0.64 ± 0.608 | 0.16 ± 0.603 |
Blood samples were collected for assessing the concentration of NT-proBNP. Baseline is defined as last non-missing measurement prior to the first dose.
| ng/L | Treatment 1 | Treatment 2 |
|---|---|---|
| Mean Change From Baseline in NT-proBNP to Week 48 | 0.42 ± 5.842 | 1.02 ± 5.655 |
Participants with \\\>= 1 NYHA function class improvement. The NYHA Functional Classification of heart failure assigns participants to 1 of 4 categories based on the participant's symptoms. Class 1: No limitation of physical activity. Ordinary physical activity does not cause undue fatigue, palpitation, dyspnea (shortness of breath). Class 2: Slight limitation of physical activity. Comfortable at rest. Ordinary physical activity results in fatigue, palpitation, dyspnea (shortness of breath). Class 3: Marked limitation of physical activity. Comfortable at rest. Less than ordinary activity causes fatigue, palpitation, or dyspnea. Class 4: Unable to carry on any physical activity without discomfort. Symptoms of heart failure at rest. If any physical activity is undertaken, discomfort increases.
| Percentage of Participants | Treatment 1 | Treatment 2 |
|---|---|---|
| Percentage of Participants With at Least 1 Class of NYHA Improvement From Baseline at Week 48 | 36.33 (30.79 to 41.88) | 31.62 (26.27 to 36.96) |
The HCMSQ is a self- administered, 9-item questionnaire that assesses the core symptoms of HCM (shortness of breath, tiredness/fatigue, heart palpitations, chest pain, dizziness, and syncope). At each visit, a 7-day period will be defined, ending on the last day with a non-missing HCMSQ score prior to the actual clinic visit (or first dose date if baseline). If the participant completes the HCMSQ for 4 or more days within this period, the weekly average HCMSQ score will be calculated. If fewer than 4 days are completed, other 7-day periods will be considered. For baseline, any 7-day period with at least 4 days of HCMSQ prior to the first dose or randomization date (if first dose date is missing) will be used. Each domain of the SoB scale is scored 1 to 6. The scores are added together to give a total score. Lower scores indicating low to no shortness of breath, higher scores indicating frequent episodes of shortness of breath. the lower the score the better.
| Score on a Scale | Treatment 1 | Treatment 2 |
|---|---|---|
| Mean Change From Baseline in HCMSQ SoB Domain Score at Week 48 | -1.76 ± 0.208 | -1.06 ± 0.207 |
The KCCQ-23 is a 23-item, self-administered questionnaire that measures the impact of a participant's cardiovascular disease or its treatment on 6 distinct domains using a 2-week recall period: symptoms/signs, physical limitation, quality of life (QoL), social limitations, self-efficacy, and symptom stability. The KCCQ 23 Clinical Summary Score (CSS) is derived from the Total Symptom Score (TSS) and the Physical Limitations (PL) score of the KCCQ 23. The CSS, TSS, and the PL score range from 0 to 100 with higher scores representing less severe symptoms and/or physical limitations. The CSS is a mean of the TSS and the PL score. Baseline is defined as the last non-missing assessment prior to the first dose of the study treatment if both the time of the measurement and the time of first dose are available otherwise it is the last non-missing assessment on or prior to the first dose of the study treatment.
| Score on a Scale | Treatment 1 | Treatment 2 |
|---|---|---|
| Change From Baseline in KCCQ-23 CSS at Week 48 | 13.13 ± 1.222 | 10.38 ± 1.214 |
Clinically meaningful mean change from baseline(1.4ml/kg/min) of pVO2 at Week 48.
| mL/kg/min | Treatment 1 | Treatment 2 |
|---|---|---|
| Change From Baseline in pVO2 at Week 48 | 0.52 ± 0.220 | 0.05 ± 0.216 |
Collected over Adverse Events and Serious Adverse Events: (From first dose to last dose + 120 days): Approximately 173 Weeks All-Cause mortality (From randomization to end of study): Approximately 178 Weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| MAVACAMTEN | 1/34 (2.9%) | 18/34 (52.9%) | 26/34 (76.5%) |
| PLACEBO | 1/19 (5.3%) | 8/19 (42.1%) | 17/19 (89.5%) |
| MAVACAMTEN/MAVACAMTEN | 1/254 (0.4%) | 63/254 (24.8%) | 201/254 (79.1%) |
| PLACEBO/MAVACAMTEN | 2/271 (0.7%) | 55/271 (20.3%) | 192/271 (70.8%) |
| Event | MAVACAMTEN | PLACEBO | MAVACAMTEN/MAVACAMTEN | PLACEBO/MAVACAMTEN |
|---|---|---|---|---|
| Atrial fibrillationCardiac disorders | 7/34 | 2/19 | 7/254 | 10/271 |
| Cardiac failureCardiac disorders | 6/34 | 1/19 | 6/254 | 5/271 |
| Cardiac failure congestiveCardiac disorders | 3/34 | 0/19 | 2/254 | 0/271 |
| Angina pectorisCardiac disorders | 0/34 | 1/19 | 3/254 | 1/271 |
| Angina unstableCardiac disorders | 0/34 | 1/19 | 0/254 | 0/271 |
| Conduction disorderCardiac disorders | 0/34 | 1/19 | 0/254 | 0/271 |
| VomitingGastrointestinal disorders | 0/34 | 1/19 | 0/254 | 0/271 |
| DeathGeneral disorders | 0/34 | 1/19 | 0/254 | 1/271 |
| Non-cardiac chest painGeneral disorders | 0/34 | 1/19 | 1/254 | 3/271 |
| Hepatocellular carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/34 | 1/19 | 0/254 | 0/271 |
| Event | MAVACAMTEN | PLACEBO | MAVACAMTEN/MAVACAMTEN | PLACEBO/MAVACAMTEN |
|---|---|---|---|---|
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 9/34 | 3/19 | 46/254 | 41/271 |
| PalpitationsCardiac disorders | 2/34 | 5/19 | 38/254 | 28/271 |
| Cardiac failureCardiac disorders | 7/34 | 0/19 | 15/254 | 15/271 |
| FatigueGeneral disorders | 4/34 | 0/19 | 46/254 | 33/271 |
| DizzinessNervous system disorders | 3/34 | 3/19 | 38/254 | 34/271 |
| Atrial fibrillationCardiac disorders | 5/34 | 2/19 | 30/254 | 25/271 |
| NasopharyngitisInfections and infestations | 2/34 | 2/19 | 36/254 | 31/271 |
| HeadacheNervous system disorders | 1/34 | 2/19 | 24/254 | 21/271 |
| COVID-19Infections and infestations | 2/34 | 0/19 | 25/254 | 24/271 |
| Atrial flutterCardiac disorders | 3/34 | 0/19 | 4/254 | 6/271 |
| Age, Continuous(Years) | Treatment 1 | Treatment 2 | Total |
|---|---|---|---|
| Mean | 56.4 ± 14.71 | 55.7 ± 14.39 | 56.0 ± 14.54 |
| Sex: Female, Male(Participants) | Treatment 1 | Treatment 2 | Total |
|---|---|---|---|
| Female | 141 | 125 | 266 |
| Male | 148 | 166 | 314 |
| Ethnicity (NIH/OMB)(Participants) | Treatment 1 | Treatment 2 | Total |
|---|---|---|---|
| Hispanic or Latino | 40 | 42 | 82 |
| Not Hispanic or Latino | 215 | 222 | 437 |
| Unknown or Not Reported | 34 | 27 | 61 |
| Race (NIH/OMB)(Participants) | Treatment 1 | Treatment 2 | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 51 | 39 | 90 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 11 | 14 | 25 |
| White | 195 | 205 | 400 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 32 | 33 | 65 |
Showing the first 100 of 224 sites across 23 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — BMS will provide access to individual anonymized participant data upon request from qualified researchers, and subject to certain criteria. Additional information regarding Bristol Myers Squibb's data sharing policy and process can be found at: https://www.bms.com/researchers-and-partners/clinical-trials-and-research/disclosurecommitment.html
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: See Plan Description
Access criteria: See Plan Description
Data sharing details ↗ · www.bms.com
Ran from Dec 2022 to primary completion in Mar 2025, 26 months.
Results were first posted in Aug 2026, 1 year 5 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: MYK-461
Cardiomyopathy, Hypertrophic →